NCT04702425: phase 1: VOB560-MIK665 Combination First in Human Trial in Patients With Hem. Malig.
Updated: May 25, 2022
VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)
The purpose of the study is to identify doses and schedules of VOB560 and MIK665 that can be safely given and to learn if the combination can have possible benefits for patients with Non-Hodgkin lymphoma (NHL), Multiple Myeloma (MM) or Acute Myeloid Leukemia (AML).
VOB560 and MIK665 are selective and potent blockers respectively of the B-cell lymphoma 2 (BCL2) protein and of the myeloid cell leukaemia 1 (MCL1) protein, proteins that may protect tumor cells from undergoing cell death. VOB560 and MIK665 are designed to block the functions of the BCL2 and MCL1 proteins, so that the tumor cells that rely on these proteins undergo cell death.
Preclinical data suggest that concomitant treatment with VOB560 in combination with MIK665 induces robust anti-tumor activity.
ClinicalTrials.gov Identifier: NCT04702425
Official Title: A Phase Ib, Multicenter Study of VOB560 in Combination With MIK665 in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma.
First Posted: January 8, 2021
Click here for details on ClinicalTrials.gov
BCL2 Inhibitor VOB560 (Code C158510)
Bcl-2 Inhibitor S65487
BCL2 Inhibitor VOB560
Mcl-1 Inhibitor MIK665 (Code C133174)
Mcl-1 Inhibitor MIK665
Korea, Republic of